UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 9, 2005
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15360
Oregon | | 93-1099680 |
(State or other jurisdiction of incorporation | | (I.R.S. Employer Identification No.) |
or organization) | | |
| | |
20245 SW 95th Avenue | | 97062 |
Tualatin, Oregon | | (Zip Code) |
(Address of principal executive offices) | | |
| | |
Registrant’s telephone number, including area code: (503) 692-8001 |
|
Former name or former address if changed since last report: |
No Change |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
BIOJECT MEDICAL TECHNOLOGIES INC.
FORM 8-K
INDEX
1
Item 1.01 Entry into a Material Definitive Agreement
We granted restricted stock unit awards to our non-employee directors and the following executive officers pursuant to our 1992 Stock Incentive Plan as follows:
Executive Officer | | Grant Date | | Number
of Shares | | Per Share
Fair Market
Value on
Date of Grant | | Vesting | |
James C. O’Shea | | 12/08/05 | | 30,000 | | $ | 1.50 | | (2) | |
Chairman, Chief Executive Officer and President | | | | | | | | | |
| | | | | | | | | |
J. Michael Redmond | | 12/08/05 | | 5,150 | | $ | 1.50 | | (2) | |
Senior Vice President, Business Development | | | | | | | | | |
| | | | | | | | | |
John Gandolfo (1) | | 12/08/05 | | 21,500 | | $ | 1.50 | | (2) | |
Former Chief Financial Officer and Vice President of Finance | | | | | | | | | |
| | | | | | | | | |
Director | | | | | | | | | |
Dr. Randal D. Chase | | 06/09/05 | | 3,000 | | $ | 1.14 | | (3) | |
William A. Gouveia | | 06/09/05 | | 3,000 | | $ | 1.14 | | (3) | |
Eric T. Herfindal | | 06/09/05 | | 3,000 | | $ | 1.14 | | (3) | |
Sandra Panem, Ph.D. | | 06/09/05 | | 3,000 | | $ | 1.14 | | (3) | |
Richard J. Plestina | | 06/09/05 | | 3,000 | | $ | 1.14 | | (3) | |
John Ruedy, M.D. | | 06/09/05 | | 3,000 | | $ | 1.14 | | (3) | |
(1) Mr. Gandolfo’s employment terminated in May 2006.
(2) Vests as to ½ on December 8, 2006 and ½ on December 8, 2007.
(3) Vests as to ½ on December 9, 2005 and ½ on June 9, 2006.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are filed herewith and this list is intended to constitute the exhibit index:
10.1 Form of Restricted Stock Unit Award Agreement for December 8, 2005 grants.
10.2 Form of Restricted Stock Unit Award Agreement for June 9, 2005 grants.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: June 27, 2006 | | BIOJECT MEDICAL TECHNOLOGIES INC. |
| | (Registrant) |
| | /s/ CHRISTINE M. FARRELL |
| | Christine M. Farrell |
| | Vice President of Finance |
| | (Principal Financial and Accounting Officer) |
3
